search
Back to results

Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant (PREP)

Primary Purpose

Pancreatic Fistula

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Pancreaticogastrostomy with external drain
Pancreaticojejunostomy with transanastomotic drain
Sponsored by
Azienda Ospedaliera Universitaria Integrata Verona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pancreatic Fistula focused on measuring Pancreaticoduodenectomy, Pancreaticogastrostomy, Pancreaticojejunostomy, Stent, Transanastomotic drain

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All the patients undergoing pancreaticoduodenectomy (only Whipple or Traverso) for all kind of pancreatic disease (benign, malignant or premalignant).
  • Patients able to give their informed consent

Exclusion criteria

  • Informed consent withdrawal
  • Impossibility to undergo surgery for any reason
  • Use of glues or biological matrices to protect the anastomosis
  • Fistula Risk Score < 7
  • Post-operative octreotide analogues administration (only prophylactic use, therapeutic use allowed)
  • Wrong randomization

Sites / Locations

  • Ospedale Policlinico GB Rossi

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Pancreaticogastrostomy

Pancreaticojejunostomy

Arm Description

Pancreaticogastrostomy with external drain

Pancreaticojejunostomy with transanastomotic drain

Outcomes

Primary Outcome Measures

Post-operative Pancreatic Fistula (POPF)
Presence of Amylase > 3 times the upper limit of normal in surgical drains at or by post-operative day 3 (POD) determining a clinically relevant change in patient's management

Secondary Outcome Measures

POPF severity
POPF grade B and grade C rates
Length of Hospital Stay
calculated from the day of surgery to the day of discharge, adding up the days after a possible re-admission
Mortality
Death related to surgical morbidity
Post-Pancreatectomy Hemorrhage
As defined by the International Study Group for Pancreatic Surgery (ISGPS), grade A, B and C rates
Delayed Gastric Emptying
As defined by ISGPS, grade A, B and C rates
Biliary fistula
Output of bile from drains on or by POD 3, pancreaticojejunostomy leak should be ruled out
Gastrojejunal/Duodenojejunal fistula
Fistula from gastro/duodenojejunostomy
Abdominal abscess
Collection >5cm in size, containing gas bubbles, determining systemic signs of infection
Acute pancreatitis
Altered serum amylase count on POD 0 or POD 1
Wound infection
Superficial and Deep Surgical Site Incisional Infection as defined by the Center for Disease Control and Prevention
Blood transfusions
Need and number of packed red blood cells transfused
Myocardial infarction
Myocardial necrosis
Acute Kidney Failure
Abrupt change in serum creatinine >1.5 baseline value
Pulmonary Embolism
Blood clots in the pulmonary arterial system
Pneumonia
Bacterial infection of the lungs
Respiratory insufficiency
Need for re-intubation
Urinary Tract Infection
Bacterial infection of the urinary tract
Cerebrovascular accidents
Stroke, hemorrhage, brain death
Reoperation
Need for new surgery due to severe morbidity
Readmission
New admission within 30-days of discharge from hospital
Time-to-adjuvant therapy
Time form index operation to the beginning of adjuvant treatment (only for malignancy)

Full Information

First Posted
November 9, 2016
Last Updated
September 12, 2019
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
search

1. Study Identification

Unique Protocol Identification Number
NCT03212196
Brief Title
Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant
Acronym
PREP
Official Title
Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant: a Risk-adjusted Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
June 12, 2017 (Actual)
Primary Completion Date
June 10, 2019 (Actual)
Study Completion Date
July 10, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Azienda Ospedaliera Universitaria Integrata Verona

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial will investigate what surgical technique between pancreaticogastrostomy and pancreaticojejunostomy with transanastomotic externalized drains is associated with the lowest rate of pancreatic fistula after pancreaticoduodenectomy in case of high-risk pancreatic remnants.
Detailed Description
Pancreatic fistula is the major determinant of outcome after pancreaticoduodenectomy. Several strategies to reduce the burden of this complication have been proposed in the last decade. A definite answer about what is the best technique to approach a high-risk pancreatic stump is still needed. Both pancreaticogastrostomy and pancreaticojejunostomy with transanastomotic externalized drains have been proposed in this setting, but often studies do not provide a reliable risk stratification and result are extremely variable. The aim of this trial is to evaluate what surgical technique, between pancreaticogastrostomy and pancreaticojejunostomy with transanastomotic externalized drains, is associated with the lowest rate of pancreatic fistula in case of high-risk pancreatic remnants. Risk stratification will be provided through the Fistula Risk Score, a clinical risk score that has been extensively validated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Fistula
Keywords
Pancreaticoduodenectomy, Pancreaticogastrostomy, Pancreaticojejunostomy, Stent, Transanastomotic drain

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pancreaticogastrostomy
Arm Type
Active Comparator
Arm Description
Pancreaticogastrostomy with external drain
Arm Title
Pancreaticojejunostomy
Arm Type
Active Comparator
Arm Description
Pancreaticojejunostomy with transanastomotic drain
Intervention Type
Procedure
Intervention Name(s)
Pancreaticogastrostomy with external drain
Intervention Description
Pancreatico-enteric anastomosis is provided according to the "Bassi technique", pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct.
Intervention Type
Procedure
Intervention Name(s)
Pancreaticojejunostomy with transanastomotic drain
Intervention Description
Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
Primary Outcome Measure Information:
Title
Post-operative Pancreatic Fistula (POPF)
Description
Presence of Amylase > 3 times the upper limit of normal in surgical drains at or by post-operative day 3 (POD) determining a clinically relevant change in patient's management
Time Frame
30 days post-operative
Secondary Outcome Measure Information:
Title
POPF severity
Description
POPF grade B and grade C rates
Time Frame
30 days post-operative
Title
Length of Hospital Stay
Description
calculated from the day of surgery to the day of discharge, adding up the days after a possible re-admission
Time Frame
1 year
Title
Mortality
Description
Death related to surgical morbidity
Time Frame
90 days
Title
Post-Pancreatectomy Hemorrhage
Description
As defined by the International Study Group for Pancreatic Surgery (ISGPS), grade A, B and C rates
Time Frame
90 days
Title
Delayed Gastric Emptying
Description
As defined by ISGPS, grade A, B and C rates
Time Frame
90 days
Title
Biliary fistula
Description
Output of bile from drains on or by POD 3, pancreaticojejunostomy leak should be ruled out
Time Frame
90 days
Title
Gastrojejunal/Duodenojejunal fistula
Description
Fistula from gastro/duodenojejunostomy
Time Frame
90 days
Title
Abdominal abscess
Description
Collection >5cm in size, containing gas bubbles, determining systemic signs of infection
Time Frame
90 days
Title
Acute pancreatitis
Description
Altered serum amylase count on POD 0 or POD 1
Time Frame
1 day post index surgery
Title
Wound infection
Description
Superficial and Deep Surgical Site Incisional Infection as defined by the Center for Disease Control and Prevention
Time Frame
90 days
Title
Blood transfusions
Description
Need and number of packed red blood cells transfused
Time Frame
90 days
Title
Myocardial infarction
Description
Myocardial necrosis
Time Frame
90 days
Title
Acute Kidney Failure
Description
Abrupt change in serum creatinine >1.5 baseline value
Time Frame
90 days
Title
Pulmonary Embolism
Description
Blood clots in the pulmonary arterial system
Time Frame
90 days
Title
Pneumonia
Description
Bacterial infection of the lungs
Time Frame
90 days
Title
Respiratory insufficiency
Description
Need for re-intubation
Time Frame
90 days
Title
Urinary Tract Infection
Description
Bacterial infection of the urinary tract
Time Frame
90 days
Title
Cerebrovascular accidents
Description
Stroke, hemorrhage, brain death
Time Frame
90 days
Title
Reoperation
Description
Need for new surgery due to severe morbidity
Time Frame
90 days
Title
Readmission
Description
New admission within 30-days of discharge from hospital
Time Frame
30 days after hospital discharge
Title
Time-to-adjuvant therapy
Description
Time form index operation to the beginning of adjuvant treatment (only for malignancy)
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All the patients undergoing pancreaticoduodenectomy (only Whipple or Traverso) for all kind of pancreatic disease (benign, malignant or premalignant). Patients able to give their informed consent Exclusion criteria Informed consent withdrawal Impossibility to undergo surgery for any reason Use of glues or biological matrices to protect the anastomosis Fistula Risk Score < 7 Post-operative octreotide analogues administration (only prophylactic use, therapeutic use allowed) Wrong randomization
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Bassi, MD
Organizational Affiliation
Università degli studi di Verona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale Policlinico GB Rossi
City
Verona
ZIP/Postal Code
37134
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual Participant Data will not be shared with other researchers
Citations:
PubMed Identifier
27730401
Citation
McMillan MT, Ecker BL, Behrman SW, Callery MP, Christein JD, Drebin JA, Fraker DL, Kent TS, Lee MK, Roses RE, Sprys MH, Vollmer CM Jr. Externalized Stents for Pancreatoduodenectomy Provide Value Only in High-Risk Scenarios. J Gastrointest Surg. 2016 Dec;20(12):2052-2062. doi: 10.1007/s11605-016-3289-6. Epub 2016 Oct 11.
Results Reference
background
PubMed Identifier
20622661
Citation
Bassi C, Molinari E, Malleo G, Crippa S, Butturini G, Salvia R, Talamini G, Pederzoli P. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. Ann Surg. 2010 Aug;252(2):207-14. doi: 10.1097/SLA.0b013e3181e61e88.
Results Reference
background
PubMed Identifier
23122535
Citation
Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013 Jan;216(1):1-14. doi: 10.1016/j.jamcollsurg.2012.09.002. Epub 2012 Nov 2.
Results Reference
background
PubMed Identifier
25040921
Citation
Hallet J, Zih FS, Deobald RG, Scheer AS, Law CH, Coburn NG, Karanicolas PJ. The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials. HPB (Oxford). 2015 Feb;17(2):113-22. doi: 10.1111/hpb.12299. Epub 2014 Jul 7.
Results Reference
background
PubMed Identifier
27017162
Citation
Wang SE, Chen SC, Shyr BU, Shyr YM. Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy. HPB (Oxford). 2016 Mar;18(3):229-35. doi: 10.1016/j.hpb.2015.09.007. Epub 2015 Nov 17.
Results Reference
background
PubMed Identifier
32101272
Citation
Andrianello S, Marchegiani G, Malleo G, Masini G, Balduzzi A, Paiella S, Esposito A, Landoni L, Casetti L, Tuveri M, Salvia R, Bassi C. Pancreaticojejunostomy With Externalized Stent vs Pancreaticogastrostomy With Externalized Stent for Patients With High-Risk Pancreatic Anastomosis: A Single-Center, Phase 3, Randomized Clinical Trial. JAMA Surg. 2020 Apr 1;155(4):313-321. doi: 10.1001/jamasurg.2019.6035.
Results Reference
derived

Learn more about this trial

Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant

We'll reach out to this number within 24 hrs